Mi2000 TICI - Post-market Implantation Study

Trial details

Who runs it

MED-EL Elektromedizinische Geräte GmbH

Trial code

NCT07897318

Record updated

12 November 2026

Original description

This Post-Market Clinical Follow-up (PMCF) investigation aims to further collect evidence on safety and performance of the Mi2000 TICI. This PMCF investigation will prospectively collect clinical data from the use of the Mi2000 TICI and related devices.Read full original descriptionShow less

This Post-Market Clinical Follow-up (PMCF) investigation aims to further collect evidence on safety and performance of the Mi2000 TICI. This PMCF investigation will prospectively collect clinical data from the use of the Mi2000 TICI and related devices.

This PMCF investigation is performed on a cochlear implant system newly introduced to the market, which was previously studied in two pre-market clinical investigations. The purpose of the current clinical investigation is to collect further evidence by collecting additional clinical data on the use of the Mi2000 TICI.

Inclusion: Minimum age of eighteen (18) years at time of enrolment; Bilateral sensorineural hearing loss with no or limited benefit from a hearing aid (>70 dB HL PTA4(500, 1000, 2000, 4000Hz)); Post-lingual onset of deafness; No or limited benefit from hearing aids for less than 10 years and an expected benefit from cochlear implantation; A maximum score of 50% on a word test in the language of the test center in the ear to be implanted in the best aided condition; Fluency in the test language with excellent proficiency, as appropriate to perform speech testing; Functional auditory nerve; General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study; Pre-operative assessment according to the local professional standards; Candidate is highly motivated and has realistic expectations about the expected benefit of the implant and shall understand the importance of returning to the implant center for regular speech processor programming, assessment sessions and training; Realistic expectations, as deemed appropriate by the implanting surgeon/implant board; Signed and dated informed consent before the start of any study-specific procedure.

Exclusion: Previously having received an implant on the location chosen for placing the cochlear implant; Having received a hearing implant from another manufacturer than MED-EL on the contralateral ear; The individual is known to be intolerant of the materials used in the implant or other required accessories; Medical contra-indications to middle ear and/or inner ear surgery, and/or anesthesia; Participation in other pharmacological clinical trials within four weeks prior to enrolment; Pre-existing condition known to necessitate MRI scans after implantation of the Mi2000 TICI; External or middle ear infections are present; History of vestibular schwannoma; Unstable Meniere's disease; Epilepsy not responding to treatment; Known intellectual disability and/or psychological diseases; Lack of compliance with any inclusion criterion; Women being pregnant or nursing; Absence of cochlear development; The cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway; The tympanic membrane is perforated in the ear to be implanted; Anatomic abnormalities are present that would prevent appropriate placement of the stimulator housing in the bone of the skull, or prevent placement of the chosen electrode array into the cochlea (including ossification of the cochlea); The psychological status of the individual is unstable; The individual has unrealistic expectations; Acute cholesteatoma; Auditory Neuropathy; Permanent inability and/or unwillingness to participation in post-operative care and rehabilitation; Anything that, in the opinion of the Investigator, would; place the subject at increased risk; preclude the subject's full compliance with or completion of the study.

ClinicalTrials.gov NCT07897318